

Myeloablative Allogeneic HSCT (Received TBI) * Pediatric Surveillance & Follow-up Guidelines

ATTACH PATIENT ID

Months from end of therapy	Date	H&P	CBC, retics LDH	Chem	Chimerism & MRD*	Endo	LH, FSH, Test or Est	Immune	Viral screen*	Other labs	Urine tests	PFTs	GFR, ECHO	DEXA BMD	Physio & Dietician	Neuropsych assessment	Other
1		+	+	+	+				+								
1.5		+	+	+					+								
2		+	+	+					+								
2.5		+	+	+					+								
3		+	+	+	+			+	+	+	+	+			+		
4		+	+	+													
5		+	+	+													
6		+	+	+	+	+	+	+	+			+		+			*1
7		+	+	+													
8		+	+	+													
9		+	+	+	+				+								
10		+	+	+													
11		+	+	+													
12		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+ Ophthalmology + Dentistry + Audiology
15		+	+	+													
18		+	+	+													
21		+	+	+													
Notes				Lytes, Ca, Mg, PO4, Cr, urea, LFTs, glucose	*if applicable Further chimerism testing >24mo PRN	TSH, T4, Vit D, IGF-1, Fasting glucose and lipids	Baseline age 12 y if CED ≥4 or clinical concerns. Rpt Q1y	T&B cell panel, IgA, IgG, IgE, IgM	EBV, CMV, Adeno. HV6 only if haplo & CBT. EBV only after 3mo	RBC pit count, blood group, ferritin	U/A, urine Prot:Cr & Alb:Cr ratio	Refer to Resp if too young to perform				Prior to school entry or if concerns	1. Attenuated vaccine re-immunizations at 6 mo if no active GVHD or ongoing immune suppression 2. sIL-2 at Dx of GVHD and 4-8wk later

* See alternate screening schedule if Graft-vs-Host Disease
If patient on study, refer to study protocol for additional testing

Further Surveillance	
Dentistry	Annual
Gynecology	PRN
Semen Analysis	From age 18y in males
Anti-Mullerian Hormone	From age 16y in females if CED ≥ 6 g/m ² or pelvic RT; or earlier if clinical concerns
Breast MRI and Mammogram	From later of age 25y or 8y after exposure if chest RT
Colonoscopy	From later of age 30y or 5y after exposure to abdominal RT

Cardiac Surveillance Guidelines (BC)

Anthracycline Dose*	Radiation Dose**	Recommended Frequency of Echo
None	< 15 Gy or none	No Screening
	15 - < 35 Gy	Every 5 years
	35 Gy	Every 2 years
< 250 mg/m ²	< 15 Gy or none	Every 5 years
	15 Gy	Every 2 years
250 mg/m ²	Any or none	Every 2 years

*Based on total doses of doxorubicin or the equivalent doses of other anthracyclines

**Based on radiation dose with potential impact to heart (radiation to chest, abdomen, spine [thoracic, whole], total body [TBI])

COG LTFU Guidelines version 5.0 (Oct 2018)

Anthracycline Equivalent Dose

Agent	Correction factor
Doxorubicin	1.0
Daunorubicin	0.5
Epirubicin	0.67
Mitoxantrone	4.0
Idarubicin	5.0

Chow J Clin Oncol 2015;33(5):394-402

Risk of Prolonged Oligospermia or Azoospermia

Agent	Possible Risk	High Risk
Cyclophosphamide	> 4g/m ²	> 7.5 g/m ²
Busulphan		> 600 mg/m ²
Melphalan		> 140 mg/m ²
Ifosfamide	> 42 g/m ²	> 60 g/m ²
Procarbazine	> 3 g/m ²	> 4 g/m ²
Chlorambucil		> 1.4 g/m ²
BCNU	> 300 mg/m ²	> 1 g/m ²
CCNU		> 500 mg/m ²
Cisplatin	> 300 mg/m ²	> 600 mg/m ²
Testicular RT dose	> 200 cGy	> 1200 cGy

*Lower doses are still possible risk

1. Green J Clin Oncol 2010;28:332-9
2. Meistrich Pediatr Blood Cancer 2009;53:261-6
3. Wyns Human Reprod Update 2010;16(3):312-328

Risk of Premature Ovarian Insufficiency or Infertility

Agent	Possible Risk	High Risk	Ref
CED	> 4 g/m ²	> 8 g/m ²	1
Procarbazine	> 2 g/m ²	> 4 g/m ²	2
Cisplatin	> 300 mg/m ²		3
Dactinomycin	>12.2 mg/m ²		4
Ovarian RT dose*	> 100 cGy	> 1000 cGy	5

*Age dependent (see nomogram⁵)

^Bevacizumab can cause ovarian failure; possibly acute and transient only⁶

1. Green Pediatr Blood Cancer 2014;61(1):53-67
2. Van der Kaaji J Clin Oncol 2012;30(3):291-299
3. Solheim Gyne Oncol 2015;136(2):224-229
4. Van Den Berg Hum Reprod 2018; 33(8):1474-1488
5. Wallace Int J Radiat Oncol;62(3):738-744
6. Imai Molec Clin Oncol 2017;6:807-810

Cyclophosphamide Equivalent Dose (CED)

Agent	Correction factor
Cyclophosphamide	1.0
Ifosfamide	0.244
Procarbazine	0.857
Chlorambucil	14.286
BCNU	15
CCNU	16
Melphalan	40
Thiotepa	50
Nitrogen Mustard	100
Busulphan	8.823

Green Pediatr Blood Ca 2014;61:53-67